Variations in the ITGA2 gene, which is crucial for cell adhesion and signaling, can significantly impact the effectiveness and safety of antiplatelet drugs such as clopidogrel and aspirin. These drugs target platelet aggregation processes, and genetic differences in ITGA2 can alter how patients respond to these medications, affecting their risk of bleeding or clotting.